P2Y12 receptor antagonism inhibits proliferation, migration and leads to autophagy of glioblastoma cells
Pedro Vargas,Thamiris Becker Scheffel,Fernando Mendonça Diz,Liliana Rockenbach,Nathália Grave,Angélica Regina Cappellari,Luiza Wilges Kist,Maurício Reis Bogo,Marcos Paulo Thomé,Gabriel Fernandes Leal,Amanda de Fraga Dias,Fabrício Figueiró,Eduardo Cremonese Filippi-Chiela,Guido Lenz,Fernanda Bueno Morrone
DOI: https://doi.org/10.1007/s11302-022-09888-w
Abstract:Glioblastoma (GBM) is the most aggressive and lethal among the primary brain tumors, with a low survival rate and resistance to radio and chemotherapy. The P2Y12 is an adenosine diphosphate (ADP) purinergic chemoreceptor, found mainly in platelets. In cancer cells, its activation has been described to induce proliferation and metastasis. Bearing in mind the need to find new treatments for GBM, this study aimed to investigate the role of the P2Y12R in the proliferation and migration of GBM cells, as well as to evaluate the expression of this receptor in patients' data obtained from the TCGA data bank. Here, we used the P2Y12R antagonist, ticagrelor, which belongs to the antiplatelet agent's class. The different GBM cells (cell line and patient-derived cells) were treated with ticagrelor, with the agonist, ADP, or both, and the effects on cell proliferation, colony formation, ADP hydrolysis, cell cycle and death, migration, and cell adhesion were analyzed. The results showed that ticagrelor decreased the viability and the proliferation of GBM cells. P2Y12R antagonism also reduced colony formation and migration potentials, with alterations on the expression of metalloproteinases, and induced autophagy in GBM cells. Changes were observed at the cell cycle level, and only the U251 cell line showed a significant reduction in the ADP hydrolysis profile. TCGA data analysis showed a higher expression of P2Y12R in gliomas samples when compared to the other tumors. These data demonstrate the importance of the P2Y12 receptor in gliomas development and reinforce its potential as a pharmacological target for glioma treatment.